Aurobindo Pharma Hosts Investor Meet Sep 24
Aurobindo Pharma to meet analysts and investors on Sep 24 at 2:30 PM. Meeting aims to discuss company updates with stakeholders. Source: Livesquawk
Stock news timeline · AUROPHARMA
Aurobindo Pharma
News timeline · Last 30 days
24 Aug 2026 – 22 Sep 2026 · Times in IST
- Timeline updates
- 35
- Bullish
- 12
- Neutral
- 22
- Bearish
- 1
- Active days
- 12
News timeline
Showing 35 of 35 updates · Newest first
No matching updates
Change the keyword or sentiment above, then click Apply.
Monday, 21 Sep 20264 updates
Aurobindo Pharma: Schedules Meeting With Analysts And Investors On September 24 At 2.30 PM.
Aurobindo Pharma Joins JP Morgan Healthcare Meet in Hyderabad on Sep 24
Aurobindo Pharma Ltd to join JP Morgan Healthcare Trip in Hyderabad. The meeting on Sep 24, 2026, won't disclose unpublished price-sensitive info. Source: BSE
Pharma Stocks Rally; BSE Healthcare Hits New High
Pharma stocks surged with BSE Healthcare index up 1.2%, hitting a new high. Laurus Labs, Aurobindo Pharma achieved new highs; Sun Pharma, Torrent rallied 3-5%. Source: Business Standard
Wednesday, 16 Sep 20261 update
Aurobindo Gets USFDA Nod for Inhaler; Telangana Plant Faces 1 Observation
USFDA issued one observation for Aurobindo Pharma's Telangana facility. Aurobindo Pharma got USFDA approval for Beclomethasone Dipropionate HFA Inhalation Aerosol. Source: Moneycontrol
Tuesday, 15 Sep 20265 updates
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-II API Facility Ends with One Procedural Note.
Aurobindo Gets USFDA Nod, Stock Falls 2%
Aurobindo Pharma gains USFDA nod for metered-dose inhaler. Its share price fell 2% in intraday trade after announcement. Source: Financial Express
Aurobindo Pharma Secures USFDA Nod for $301M QVAR Generic
Aurobindo Pharma gets USFDA final approval for Beclomethasone Dipropionate HFA Inhalation Aerosol. Product, a generic of QVAR, targets a US market worth $301M as of July 2026. Source: ScoutQuest
Aurobindo Pharma: Gains USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol, 40 MCG And 80 MCG; First MDI Product Set To Launch Soon; US Market Worth Estimated At $301 Million.
Aurobindo's Apitoria Unit-IV Clears US FDA Inspection
Aurobindo Pharma's subsidiary Apitoria's Unit-IV API facility passed US FDA inspection with zero observations. Source: Livesquawk
Saturday, 12 Sep 20261 update
Aurobindo Pharma Acquires A1 Biochem USA to Boost R&D Expansion
Aurobindo Pharma's unit fully acquired A1 Biochem USA for R&D services. The acquisition aims to expand pharma contract research in the USA. Source: ScoutQuest
Friday, 11 Sep 20265 updates
Aurobindo Pharma's AP Plant Clears US FDA Inspection; Shares Up 0.39%
Aurobindo Pharma's Andhra Pradesh facility passed US FDA inspection with zero observations. Shares of Aurobindo Pharma closed at ₹1,675.45, up 0.39% on BSE after the news. Source: CNBC TV 18
Aurobindo Pharma: US FDA Inspection of Subsidiary Apitoria's Unit-IV API Facility Ends with No Issues
Aurobindo Pharma's API Unit Clears US FDA Inspection
US FDA inspected Aurobindo Pharma's API unit from Sept 7-11, 2026. Inspection concluded with no observations, affirming quality commitment. Source: ScoutQuest
Aurobindo Pharma: Company Will Meet Analysts And Investors On September 22 At 9 AM.
Aurobindo Pharma to Join ICICI Securities Investor Meet on Sep 17
Aurobindo Pharma will attend an investor meeting by ICICI Securities on Sep 17, 2026. No unpublished price-sensitive information will be discussed during the meeting. Source: BSE
Tuesday, 08 Sep 20261 update
Aurobindo Pharma Gains 1.19%, Outpaces NIFTY & Pharma Index
Aurobindo Pharma rose 1.19% to Rs 1679.8, outperforming NIFTY (-0.52%) and Nifty Pharma (+0.74%). The stock gained 60.9% in one year vs a 4.9% drop in NIFTY and 21.9% dip in Nifty Pharma. Source: Business Standard
Thursday, 03 Sep 20262 updates
Aurobindo Pharma: Rumors About Block Deal Involving Promoter. - NDTV Profit
Aurobindo Pharma: Rumors About Block Deal Involving Promoter.
Tuesday, 01 Sep 20264 updates
Aurobindo Pharma Launches 100% Subsidiary Avogent for ₹5 Cr
Aurobindo Pharma forms Avogent Lifesciences Pvt Ltd for manufacturing, marketing pharma in India, abroad. The subsidiary is 100% owned with an initial share capital of Rs. 5 crores. Source: ScoutQuest
Aurobindo Pharma: Forms New Subsidiary 'Avogent Lifesciences Private Limited' With ₹5 Crore Initial Capital And No Regulatory Approvals Needed.
HSBC Keeps 'Buy' on Aurobindo, Sets ₹1,900 Target
HSBC maintains Buy on Aurobindo Pharma, target price ₹1,900. Subsidiary Lannett targets US$650mn market with generic Advair Diskus. Source: Livesquawk
Aurobindo Pharma: HSBC on Aurobindo Pharma Maintains Buy with Target Price of ₹1,900 as subsidiary Lannett launched generic Advair Diskus in the US, targeting a market above US$650mn with limited competition, providing a significant growth opportunity.
Monday, 31 Aug 20264 updates
Aurobindo US Launches Advair Generic, Eyes $60–70M Market
Aurobindo Pharma's US arm launches Advair generic, targeting $60–70M market. Source: ScoutQuest
Aurobindo Pharma Gains 3.4%, Extends Winning Streak to 5 Days
Aurobindo Pharma rises 3.4%, marking its fifth consecutive session of gains. Brief market update by Capital Market, no detailed insights available. Source: Business Standard
Aurobindo Pharma: Lanett Company LLC Introduces Generic Advar Diskus® In The US; It’s The First Product From Their Inhalation Pipeline For Asthma And COPD Treatment.
Aurobindo's Unit Launches Generic Advair in US, Marks Inhalation Debut
Aurobindo Pharma's subsidiary, Lannett Company LLC, launched a generic version of Advair Diskus in the US. This marks Aurobindo's first US inhalation product, advancing its portfolio of complex therapies. Source: BSE
Friday, 28 Aug 20263 updates
US FDA Flags 3 Issues at Aurobindo's Unit-VI
US FDA inspects Aurobindo Pharma's Unit-VI, flags three issues. Inspection concerns pertain to facility/operations at Apitoria Pharma. Source: Livesquawk
Aurobindo Subsidiary Gets 3 FDA Observations, Plans Swift Response
US FDA inspected Aurobindo Pharma's subsidiary API plant, Aug 24-28, 2026. Inspection resulted in 3 procedural observations; company to respond promptly. Source: ScoutQuest
Aurobindo Pharma: US FDA Finishes Inspection Of Apitoria Pharma's Unit-VI; Three Issues Found.
Tuesday, 25 Aug 20261 update
Aurobindo Pharma: To Hold Meeting With Analysts And Investors On September 1
Monday, 24 Aug 20264 updates
USFDA Flags Aurobindo Unit; No Data Issues
USFDA issued observation to Aurobindo Pharma's Telangana unit. Company clarified it isn't related to data integrity or GMP compliance. Source: Moneycontrol
USFDA Observations Hit Caplin, Natco; Jubilant Gains on New Approval
USFDA issued 10 observations to Caplin Point, 4 to Natco Pharma, and 1 to Aurobindo Pharma post inspections. Jubilant Pharmova's US arm received approval for a new product line. Shares of all 4 pharma firms saw varied movements. Source: CNBC TV 18
Aurobindo Pharma: Co's Subsidiary, Lannett Company LLC, Faces Four Compliance Issues After US FDA Inspection
Aurobindo's Lannett Gets 4 FDA Observations, Vows Timely Compliance
Aurobindo Pharma's subsidiary Lannett Co. LLC completed US FDA inspection with 4 procedural observations. The company will respond to US FDA within the stipulated timeline and maintain compliance standards. Source: BSE